Literature DB >> 10705698

Mandibular osteomyelitis caused by Blastoschizomyces capitatus in a child with acute myelogenous leukemia.

M Y Cheung1, N C Chiu, S H Chen, H C Liu, C T Ou, D C Liang.   

Abstract

A 6-year-old girl with acute myelogenous leukemia (AML) developed fungal mandibular osteomyelitis during chemotherapy. Blastoschizomyces capitatus was recognized histologically by its yeast-like morphology and formation of annelloconidia, and was confirmed by culture. The fungal osteomyelitis of the mandible was treated successfully with prolonged antifungal medication, extensive surgical debridement and an oral care program, without interrupting leukemia chemotherapy. B. capitatus osteomyelitis of the mandible may occur during chemotherapy in AML patients with poor dental condition. Successful treatment can be achieved by careful management without interruption of antineoplastic chemotherapy.

Entities:  

Mesh:

Year:  1999        PMID: 10705698

Source DB:  PubMed          Journal:  J Formos Med Assoc        ISSN: 0929-6646            Impact factor:   3.282


  3 in total

1.  [A 19-year-old patient with acute promyelocytic leukemia and knee swelling].

Authors:  S Böck; C Schulz; C-U Schulz; S Weckbach; E Hiller
Journal:  Internist (Berl)       Date:  2006-06       Impact factor: 0.743

Review 2.  Invasive infections caused by Trichosporon species and Geotrichum capitatum in patients with hematological malignancies: a retrospective multicenter study from Italy and review of the literature.

Authors:  Corrado Girmenia; Livio Pagano; Bruno Martino; Domenico D'Antonio; Rosa Fanci; Giorgina Specchia; Lorella Melillo; Massimo Buelli; Giampaolo Pizzarelli; Mario Venditti; Pietro Martino
Journal:  J Clin Microbiol       Date:  2005-04       Impact factor: 5.948

Review 3.  Spondylodiscitis due to an emergent fungal pathogen: Blastoschizomyces capitatus, a case report and review of the literature.

Authors:  Aygul Dogan Celik; Resat Ozaras; Serda Kantarcioglu; Ali Mert; Fehmi Tabak; Recep Ozturk
Journal:  Rheumatol Int       Date:  2009-04-16       Impact factor: 2.631

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.